Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab with SBRT in Resectable Hepatocellular Carcinoma
NCT07027436Phase 3Recruiting
- Sponsor
- Hamilton Health Sciences
- Start
- Nov 2025
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab, tremelimumab in hepatocellular carcinoma (HCC), sponsored by Hamilton Health Sciences. Started Nov 2025; status: recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07027436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07027436.